RxDoctor Payments Data

Niraj Doctor, MD

Cardiovascular Disease · Bakersfield, CANPI 1285925883

Payments from drug & device makers

$3,921in general payments, 2019–2025

Across 188 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$634
  • Merck$486
  • Novartis$456
  • Abbott$262
  • Medtronic$240
  • Irhythm Technologies, Inc.$198
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,921100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,921 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$2,406,351
Medicare patients
1,567
Services billed
21,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban378$380,906
XareltoRivaroxaban124$123,557
FarxigaDapagliflozin Propanediol86$59,289
EntrestoSacubitril/Valsartan59$58,511
JardianceEmpagliflozin60$57,533
OzempicSemaglutide38$38,397
Repatha SureclickEvolocumab43$30,026
Repatha SyringeEvolocumab36$23,520
Amiodarone Hcl474$14,199
Atorvastatin Calcium996$8,799
Praluent PenAlirocumab12$5,475
Nifedipine ErNifedipine216$5,467
ClopidogrelClopidogrel Bisulfate546$5,286
VascepaIcosapent Ethyl14$5,164
Bumetanide126$5,125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$380,906378 claims
AstraZenecaFarxiga$73$59,28986 claims
NovartisEntresto$456$58,51159 claims
Boehringer IngelheimJardiance$13$57,53360 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →